Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;31(5):327–333. [Article in Spanish] doi: 10.1016/S0212-6567(03)79187-2

Cambios previsibles en el calendario vacunal infantil en los próximos años

J Pericas Bosch 1,*
PMCID: PMC7679765  PMID: 12681149

The content is available as a PDF (70.5 KB).

Bibliografía general

  • 1.American Academy of Pediatrics Committee on Infectious Diseases. Policy Statement: Recommendations for the prevention of pneumococcal infections including the use of pneumococcal conjugated vaccine (Prevnar), pneumococcal polysaccharide vaccine and antibiotic prophylaxis (RE9960) Pediatrics. 2000;106:362–366. doi: 10.1542/peds.106.2.362. [DOI] [PubMed] [Google Scholar]
  • 2.American Academy of Pediatrics Committee on Infectious Diseases. Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Pediatrics. 1999;104:1404–1406. doi: 10.1542/peds.104.6.1404. [DOI] [PubMed] [Google Scholar]
  • 3.American Academy of Pediatrics Committee on Infectious Diseases. Recommended Childhood Immunization Schedule-United States, 2002. Pediatrics. 2002;109:162. [Google Scholar]
  • 4.American Academy of Pediatrics Committee on Infectious Diseases. Varicella vaccine update. Pediatrics. 2000;105:136–141. [PubMed] [Google Scholar]
  • 5.Belshe R.B., Mendelman P.M., Treanor J., Kings, Gruber W.L., Piedra P. The efficacy of live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1405–1412. doi: 10.1056/NEJM199805143382002. [DOI] [PubMed] [Google Scholar]
  • 6.Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R. Eficacia, seguridad e inmunogenicidad de la vacuna conjugada antineumocócica heptavalente en niños. Pediatr Infect Dis J. 2000;19:187–195. [Google Scholar]
  • 7.Black S., Shinefield H.R., Hansen J., Elvin L., Laufer L., Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis. 2001;20:1105–1107. doi: 10.1097/00006454-200112000-00002. [DOI] [PubMed] [Google Scholar]
  • 8.Campins M., Cheng H.K., Forsyth K., Guiso N., Halperi S., Huang L.M. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine. 2001;20:641–646. doi: 10.1016/s0264-410x(01)00393-0. [DOI] [PubMed] [Google Scholar]
  • 9.Campins M., Moraga F.A. La tos ferina en el adolescente y el adulto. Epidemiología e implicaciones para la vacunación. Med Clin (Barc) 2000;114:661–664. doi: 10.1016/s0025-7753(00)71394-7. [DOI] [PubMed] [Google Scholar]
  • 10.CDC General recommendations on immunization: recommendation of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) MMWR. 2002;51(RR-2):1–36. [PubMed] [Google Scholar]
  • 11.CDC Poliomyelitis Prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 2000;49(RR-05):1–22. [PubMed] [Google Scholar]
  • 12.CDC Preventing pneumococcal disease among infants and young children. Recommendations of the Advissory Committee on Immunization Practices (ACIP) MMWR. 2000;49(RR-09):1–38. [PubMed] [Google Scholar]
  • 13.CDC Prevention of Varicella. Updated Recomendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 1999;48(RR-06):1–5. [PubMed] [Google Scholar]
  • 14.Chartrand S.A. Varicella Vaccine. Ped Clin North America. 2000:373–394. doi: 10.1016/s0031-3955(05)70212-1. [DOI] [PubMed] [Google Scholar]
  • 15.Comité Asesor de Vacunas de la Asociación Española de Pediatría. Manual de Vacunas en Pediatría. Edición 2001. Madrid; 2001. [Google Scholar]
  • 16.Comité Asesor de Vacunas de la Asociación Española de Pediatría Calendario Vacunal de la Asociación Española de Pediatría 2001–2002. An Esp Pediatr. 2001;55:30–38. [PubMed] [Google Scholar]
  • 17.Comité Asesor de Vacunas de la Asociación Española de Pediatría La enfermedad neumocócica y su prevención. Vacuna neumocócica conjugada heptavalente. An Esp Pediatr. 2002;56:79–90. [PubMed] [Google Scholar]
  • 18.Díez J., Ridao M., Latour J., Ballester A., Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine. 1999;17:1306–1311. doi: 10.1016/s0264-410x(98)00394-6. [DOI] [PubMed] [Google Scholar]
  • 19.Dirección General de Salud Pública. Consejería de Sanidad de la Comunidad de Madrid. Prevención de la enfermedad neumocócica. Disponible en: www.comadrid.es/sanidad/salud/preven/pdf/neumococo.pdf
  • 20.García-Corbeira P., Dal-Ré R., Aguilar L., García de Lomas J. Seroepidemiology of Bordetella pertussis infections in the spanish population: a cross-sectional study. Vaccine. 2000;18:2173–2176. doi: 10.1016/s0264-410x(00)00029-3. [DOI] [PubMed] [Google Scholar]
  • 21.Giebink G. The prevention of pneumococcal disease in children. N Engl J Med. 2001;16:1177–1183. doi: 10.1056/NEJMra010462. [DOI] [PubMed] [Google Scholar]
  • 22.Halperin S. Should all adolescents and adults be vaccinated against pertussis? Infect Med. 2001;18:473–475. [Google Scholar]
  • 23.Hernández A., Ruiz J., Arístegui J. Erradicación de la poliomielitis: papel de las vacunas en los próximos años en España. Acta Pediatr Esp. 2002;60:2–13. [Google Scholar]
  • 24.Lee C.H., Lee L., Koizumi K. Polysaccharide vaccines for prevention of encapsulated bacterial infections: Part 1. Infect Med. 2002;19:127–133. [Google Scholar]
  • 25.Lee C.H., Lee L., Koizumi K. Polysaccharide vaccines for prevention of encapsulated bacterial infections: Part 2. Infect Med. 2002;19:179–182. [Google Scholar]
  • 26.Merino M. Calendarios de vacunación españoles. Web de la Asociación Española de Pediatría de Atención Primaria. Disponible en: www.aepap.org/calvaces.htm
  • 27.National Advisory Committee on Immunization Statement on adult/adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Canada Communicable Disease Report (CCDR) 2000;26(ACS-1):1–8. [PubMed] [Google Scholar]
  • 28.National Advisory Committee on Immunization Statement on recommended use of pneumococcal conjugate vaccine. Canada Communicable Disease Report (CCDR) 2002;28(ACS 2):1–32. [PubMed] [Google Scholar]
  • 29.Pericas J. Vacunas en la infancia y adolescencia: Web de la Asociación Española de Pediatría de Atención Primaria: Disponible en: www.aepap.org/previnfad/Vacunas.htm
  • 30.Pericas J. Vacunas en la infancia y adolescencia: vacunas no sistemáticas. Web de la Asociación Española de Pediatría de Atención Primaria: Disponible en: www.aepap.org/previnfad/Vacunas2.htm
  • 31.Plotkin S.A. Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis. Rev Med Virol. 1997;7:75–81. doi: 10.1002/(sici)1099-1654(199707)7:2<75::aid-rmv192>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  • 32.Plotkin S.A. Vaccines in the 21st century. Infect Dis Clin North Am. 2001;15:307–327. doi: 10.1016/s0891-5520(05)70280-4. [DOI] [PubMed] [Google Scholar]
  • 33.Plotkin S.A., Orenstein W.A. Vaccines. 3rd ed. Saunders Company; Philadelphia: 1999. [Google Scholar]
  • 34.Poland G.A., Murray D., Bonilla R. New vaccine development. BMJ. 2002;324:1315–1319. doi: 10.1136/bmj.324.7349.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Prevention health care, 2001 update: use of varicella vaccine in healthy populations. CMAJ. 2001;94:1888–1889. [Google Scholar]
  • 36.Recommendations of the Advisory Committee on Immunization Practices (ACIP) Prevention and Control of Influenza. MMWR. 2002;51(RR-3):1–36. [PubMed] [Google Scholar]
  • 37.Rennels M. Combination vaccines. Pediatric Infect Dis J. 2002;21:255–257. doi: 10.1097/00006454-200203000-00018. [DOI] [PubMed] [Google Scholar]
  • 38.Salleras L. Vacunaciones Preventivas: Principios y Aplicaciones. Masson; Barcelona: 1998. [Google Scholar]
  • 39.Salleras L., Arístegui J. Vacunación frente a la varicela: ¿Selectiva o universal? Vac Invest Pract. 2001;2(Supl 1):1–4. [Google Scholar]
  • 40.Salleras L., Domínguez A., Vidal J., Plans P., Saleras M., Taberner J.L. Seroepidemiology of varicella zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine. 2000;19:183–188. doi: 10.1016/s0264-410x(00)00178-x. [DOI] [PubMed] [Google Scholar]
  • 41.Shinefield H.R., Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J. 2000;19:394–397. doi: 10.1097/00006454-200004000-00036. [DOI] [PubMed] [Google Scholar]
  • 42.Skull S.A., Wang E.L. Varicella vaccination –a critical review of the evidence. Arch Dis Child. 2001;85:83–90. doi: 10.1136/adc.85.2.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A tool for decissionmaking. Institute of Medicine (IOM) 2001. Disponible en: www.nap.edu/catalog/5501.html [PubMed]
  • 44.Vaqué J. Vacunas para el siglo XXI. Perspectivas y prioridades. In: Cam-pins M., Moraga F., editors. Vacunas 2001. Prous Science; Barcelona: 2001. pp. 271–283. [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES